Eli Lilly jet returns to Seattle after San Francisco stop amid West Coast business push

Eli Lilly and Company dispatched its Gulfstream G500, tail number N307EL, from San Francisco International Airport to King County International Airport in Seattle on May 7, 2026. The 1-hour-48-minute hop covered 43000 feet at speeds up to 498.7 knots, touching down around 10:30 p.m. local time after departing just after 1:40 p.m. Pacific.

The timing aligns with Eli Lilly and Company's freshly reported first-quarter 2026 financial results, which showed revenue climbing 56% to $19.8 billion, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound, per the company's press release this week. Seattle, a burgeoning biotech hub, hosts Eli Lilly and Company's government affairs office at 603 Stewart Street, suggesting the trip supports regulatory discussions or partnership scouting in the region—where the firm has spotlighted investment opportunities, as noted in Life Science Washington's April event series.

This jaunt fits a pattern of West Coast shuttling for Eli Lilly and Company, whose recent flights on May 6 traced routes from Sioux Falls to Seattle and then to San Francisco, amid a flurry of domestic hops from its Indianapolis headquarters. With recurring jaunts to hubs like Chicago and New York, but increasing Pacific activity, the pharma titan appears methodically expanding its footprint beyond the heartland.